Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.
Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.
Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.
Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.
Enanta Pharmaceuticals (NASDAQ: ENTA) has announced plans to report its financial results for the first fiscal quarter ended December 31, 2022, on February 7, 2023, after market close. The management will conduct a conference call at 4:30 p.m. ET to discuss these results and provide updates on ongoing research and development initiatives. Enanta focuses on developing small molecule drugs targeting viral infections, including COVID-19, RSV, and hepatitis B. It receives funding through royalties from its collaboration with AbbVie, particularly from the HCV treatment drug, Glecaprevir.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced progress on its COVID-19 and RSV programs, highlighting the ongoing Phase 2 SPRINT trial for EDP-235, a 3CL protease inhibitor, with data expected in H1 2023. New preclinical data indicates EDP-235 can prevent COVID-19 transmission. Enanta is also expanding its antiviral portfolio, announcing a new research program for SARS-CoV-2 Papain-Like Protease inhibitors and targeting dual-inhibitors for hMPV and RSV, with candidate selection planned for Q4 2023. CEO Jay R. Luly will provide updates during the J.P. Morgan Healthcare Conference on January 10, 2023.
Enanta Pharmaceuticals (NASDAQ:ENTA) will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. CEO Jay R. Luly, Ph.D., will lead the presentation, which will be available via a live webcast on Enanta's website. Following the event, a replay will be accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including COVID-19, respiratory syncytial virus, and hepatitis B, backed by royalties from its successful hepatitis C collaborations with AbbVie.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in two upcoming investor conferences. The events include a Fireside Chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 2:00 p.m. ET, and a session at the Evercore ISI 5th Annual HealthCONx Conference on November 30 at 3:30 p.m. ET. Live webcasts will be available on Enanta's website, with replays accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including RSV, COVID-19, and HBV.
Enanta Pharmaceuticals (NASDAQ: ENTA) plans to report its fiscal Q4 and full-year financial results for the period ending September 30, 2022, on November 21, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide business updates, including developments in its research and development pipeline targeting respiratory syncytial virus, SARS-CoV-2, and hepatitis B virus. Funding for these activities is supported by royalties from its collaboration with AbbVie on hepatitis C virus treatments.
Enanta Pharmaceuticals has initiated the SPRINT clinical trial for EDP-235, a 3CL protease inhibitor targeting COVID-19. This Phase 2 study evaluates the safety and effectiveness of EDP-235 in non-hospitalized adults with mild to moderate symptoms. Previous Phase 1 results indicated promising safety and potent antiviral activity against the Omicron variant. EDP-235 aims to provide a convenient once-daily treatment option. The trial will enroll approximately 200 participants, with data expected to be reported in the first half of 2023.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data for its COVID-19 treatment, EDP-235, presented at IDWeek 2022 in Washington, DC. The data indicates EDP-235 effectively penetrates target tissues, including macrophages and monocytes, potentially mitigating cytokine storms in high-risk patients. Enanta plans to initiate a Phase 2 study of EDP-235 this quarter. The drug showed favorable safety and pharmacokinetics in earlier studies, positioning it as a potential best-in-class antiviral.
Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated its Phase 1 clinical trial for EDP-323, an oral L-protein inhibitor targeting respiratory syncytial virus (RSV). This milestone follows promising preclinical data indicating EDP-323's effectiveness across RSV genotypes. The trial will enroll around 80 healthy participants to assess safety and pharmacokinetics, including randomized doses of EDP-323 and a placebo. RSV poses significant health risks, especially in young children and older adults. With EDP-323, Enanta aims to enhance its RSV treatment portfolio while potential benefits for patients are anticipated.
Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated a Phase 2b study to assess the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults at high risk of complications from acute respiratory syncytial virus (RSV) infection. The study will involve approximately 180 participants treated with EDP-938 or placebo over 5 days, with evaluations made for 28 days post-treatment. Previous studies indicated EDP-938's ability to significantly reduce RSV RNA levels and its favorable safety profile, supporting its potential for optimal clinical benefit.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data on EDP-323, a novel non-nucleoside RSV L-inhibitor, and advancements in virology methods for RSV and hMPV research. Presented at the 12th International RSV Symposium, EDP-323 showed potent inhibition of RSV replication in various models, including a mouse infection model that demonstrated improved lung histopathology. The company's research is supported by royalties from its collaboration with AbbVie on hepatitis C treatments, aiding the advance of its pipeline for respiratory viral infections.
